Healthcare Insights
7 most utilized drugs to treat type 2 diabetes
Diabetes is on the rise in the United States. Experts project the prevalence of this chronic disease will affect more than 54.9 million individuals in the U.S. by 2030. As a result, we can expect to see annual medical and societal costs top $622 billion by 2030.
Type 2 diabetes is the most common form of diabetes, affecting 90-95% of diabetes patients.
Using Definitive Healthcare’s Passport Express-Type 2 Diabetes Edition, we analyzed type 2 diabetes drugs by patient share for 2020-21 vs. 2021-2022. The table below lists the top type 2 diabetes drugs by patient share. Since some patients receive a combination of treatments (e.g. insulin injection and oral medication), the percentages in the columns add up to more than 100%.
| Rank | Drugs | 2020-2021 | 2021-2022 | Explore dataset |
|---|---|---|---|---|
| 1 | Metformin | 69.10% | 68.20% | Explore |
| 2 | Insulin | 26.80% | 24.90% | Explore |
| 3 | Sulfonylureas | 25.80% | 23.90% | Explore |
| 4 | GLP-1 agonists | 13.90% | 18.30% | Explore |
| 5 | SGLT-2 inhibitors | 12.40% | 15.70% | Explore |
| 6 | DPP-4 inhibitors | 11.10% | 10% | Explore |
| 7 | Thiazolidinediones | 5.90% | 5.90% | Explore |
Fig. 1 This table illustrates how the type 2 diabetic patient share for drug have changed from June 1, 2021 to May 31, 2022 compared with June 1, 2020 to May 31, 2021. This analysis is from Definitive Healthcare’s Passport Express-Type 2 Diabetes Edition, which combines and analyzes data from Definitive Healthcare’s ClaimsMx and ClaimsRx products.
What is the year-over-year change in type 2 diabetes drugs by patient share?&
Three out of the seven top drugs for type 2 diabetes exhibited a year-over-year (YoY) decrease in patient share, while two out of the seven exhibited a YoY increase in patient share. Insulin and sulfonylureas both exhibited the greatest decrease at 1.9%, while GLP-1 agonists exhibited the greatest increase at 4.4%. This increase in patient share for GLP-1 agonists is likely due to its clinical advantages of decreasing heart failure, renal dysfunction, and high blood pressure, which are common to diabetic patients.
What causes diabetes?
Diabetes is a condition in which a person’s body does not make enough insulin or use its insulin effectively.
Type 1 diabetes is caused by an autoimmune condition that prevents the body from producing insulin, accounting for about 5-10% of diabetes patients.
Type 2 diabetes can develop when a person’s blood glucose is too high, either due to their pancreas not creating enough insulin or the body becoming insulin resistant. High blood glucose can lead to serious health problems including heart disease, stroke, or death.
Learn more about accessing intelligence for your therapy area
Healthcare Insights are developed with healthcare commercial intelligence from the Definitive Healthcare platform.
Pharmaceutical companies developing new type 2 diabetes drugs or combination-use drugs can accelerate pre-launch planning with up-to-date and comprehensive visibility into patient and brand market share for a therapy area.
Want even more insights for your therapy area? Start a free trial now for Passport Express and get access to the latest healthcare commercial intelligence on patient and brand market.
You might also be interested in...
